New Delhi, Mar 11 (UNI) Leading drugmaker Cadila Healthcare Ltd today said its joint venture partner, Nycomed, plans to transfer bulk drug manufacturing from its Austrian and German units to their venture, Zydus Nycomed Healthcare Pvt Ltd.
This would result in the equal joint venture manufacturing of 18 active pharmaceutical ingredients (API), or bulk drugs, for four years, a company statement said.
The new development comes in the wake of both companies deciding to expand the scope of the existing JV Agreement and signing a letter of agreement to this effect.
The JV company was set up in 1999 to manufacture key starting materials for the production of Pantoprazole at Navi Mumbai.
The JV currently manufactures raw materials for pantoprazole, which is used to treat heart burn.
UNI SR PBB BD2045